Jong Hwan Sung

Title: Innovations of Jong Hwan Sung in Microfluidic Technology.

Introduction

Jong Hwan Sung is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of microfluidics, particularly in the development of devices that enhance drug discovery processes. His innovative work focuses on creating systems that allow for more accurate pharmacokinetic and pharmacodynamic studies.

Latest Patents

Jong Hwan Sung holds a patent for a microfluidic device designed for pharmacokinetic-pharmacodynamic studies of drugs. This device, termed a microscale cell culture analog (μCCA), enables the culturing of multiple cell or tissue types in a physiologically relevant environment. The microfluidic device facilitates high-throughput operations and eliminates the need for pumps, thereby reducing the risk of air bubble formation. It employs gravity-induced fluidic flow and utilizes reciprocating motion between connected reservoirs to achieve this flow in microfluidic channels. The integration of a pharmacokinetic-pharmacodynamic model allows for on-chip analyses, providing a more realistic prediction of drug toxicity compared to conventional systems. Jong Hwan Sung has 1 patent to his name.

Career Highlights

Jong Hwan Sung is affiliated with Cornell University, where he continues to advance research in microfluidic technologies. His work has garnered attention for its potential applications in drug discovery and development.

Collaborations

One of his notable collaborators is Michael L. Shuler, with whom he has worked on various projects related to microfluidic devices and their applications in pharmacology.

Conclusion

Jong Hwan Sung's contributions to microfluidic technology represent a significant advancement in the field of drug discovery. His innovative approaches are paving the way for more effective and realistic drug testing methodologies.